Cbrl-002.rar

KSP inhibitors have shown clinical promise, but toxicity and resistance mutations (e.g., T107I) limit utility. CBRL-002 was discovered from a chemoinformatics screen of 50,000 compounds. We hypothesized that a novel scaffold might overcome resistance.

A. H. Rahman¹, L. M. Chen², J. P. O’Sullivan³ ¹Institute of Molecular Pharmacology, ²Department of Computational Biology, ³Oncology Translational Research Unit CBRL-002.rar